Sinasprite and Clinical Validation
Sinasprite was one of the first digital solutions to establish clinical validation.
The Ohio State University’s peer-reviewed analysis determined that a few minutes of weekly use, Sinasprite delivered a “clinically relevant improvement,” and players were productive two more days each week than before they were introduced to Sinasprite.
We are a recognized thought leader by the scientific, health, and gaming community. We have presented research at national conferences hosted by the American Psychiatric Association, Stanford Medicine X, American Psychological Association, Consumer Technology Association, and Prevent Cancer Foundation. Policy leaders have invited Litesprite’s to present our innovation at U.S. State Department and WA State Dept of Commerce private roundtables with policy leaders including HHS Deputy Secretary Eric Hargan, US Sen. Maria Cantwell, US Rep. Susan DelBene, and FCC Commissioner Rosenworcel.
Internal findings consistently show:
Players with moderate to severe anxiety or depression reported the most improvement - a group that has difficulty engaging in therapy.
- 55% of all users achieved clinically meaningful outcomes.
- 35% of users achieve a clinically relevant improvement in symptoms of anxiety and depression
- 19% of users reported a minimally clinically significant difference (MCID) in Anxiety
- 12% of users reported an MCID in depression
For comparison purposes, an MCID requires a 4-point improvement, whereas a clinically relevant improvement requires a 2-point improvement. For reference, pharmaceutical therapeutics take a minimum of six weeks to show improvements. Both therapeutics – our game and traditional prescriptions – base clinical results on two industry-standard screening tools, the Patient Health Questionnaire 8 (PHQ-8) for depression and General Anxiety Disorder 7-Item (GAD-7) for anxiety. Other digital therapeutics are working toward this level of clinical validation.